Active	Status	Sponsor type	Region	Phase	Filter
18 Active 15 Inactive 33 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Chen, Eric X
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer	Recruiting	3	711	Europe, Canada, Japan, US, RoW	Dostarlimab, CAPEOX, FOLFOX	GlaxoSmithKline	Colonic Neoplasms, Neoplasms, Colon	12/28	12/30
NCT05605509: RP-6306 in Patients With Advanced Cancer	Recruiting	2	78	Canada	RP-6306, Lunresertib, Gemcitabine, FOLFIRI Protocol, Trastuzumab, RP-3500, Camonsertib	Canadian Cancer Trials Group, Repare Therapeutics	Advanced Cancer	12/25	05/26
NCT06776250: Study of How Safe and Effective Tarlatamab is in Brain Cancers	Not yet recruiting	2	44	Canada	Tarlatamab	University Health Network, Toronto, Amgen	Astrocytic Tumor, Oligodendroglial Tumor	03/28	03/28
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer	Active, not recruiting	2	154	Europe, Canada, Japan, US, RoW	Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A	GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd	Neoplasms, Rectal	11/26	10/29
SLC-0111-17-01, NCT03450018: A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX	Terminated	1/2	6	Canada	SLC-0111, WBI-5111, Gemcitabine Injection, Gemcitabine	British Columbia Cancer Agency, Canadian Cancer Society (CCS), SignalChem Lifesciences Corporation	Metastatic Pancreatic Ductal Adenocarcinoma	05/24	05/24
KEYNOTE-E58, NCT04041310: Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors	Active, not recruiting	1/2	115	Europe, Canada, US	GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®, pembrolizumab	Nouscom SRL, Merck Sharp & Dohme LLC	Solid Tumor, Adult	04/25	11/26
ELIMYN18.2, NCT04404595: Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers	Active, not recruiting	1/2	110	Canada, US	CT041	CARsgen Therapeutics Co., Ltd.	Gastric Cancer, Pancreatic Cancer	06/25	09/35